BACKGROUND: The fundamental principle of oncologic surgery is the complete resection of malignant cells. However, small tumors are often difficult to find during surgery using conventional techniques. The objectives of this study were to determine if optical imaging, using a contrast agent already approved for other indications, could improve hepatic metastasectomy with curative intent, to optimize dose and timing, and to determine the mechanism of contrast agent accumulation. METHODS: The high tissue penetration of near-infrared (NIR) light was exploited by use of the FLARE (Fluorescence-Assisted Resection and Exploration) image-guided surgery system and the NIR fluorophore indocyanine green in a clinical trial of 40 patients undergoing hepatic resection for colorectal cancer metastases. RESULTS: A total of 71 superficially located (< 6.2 mm beneath the liver capsule) colorectal liver metastases were identified and resected using NIR fluorescence imaging. Median tumor-to-liver ratio was 7.0 (range, 1.9-18.7) and no significant differences between time points or doses were found. Indocyanine green fluorescence was seen as a rim around the tumor, which is shown to be entrapment around cytokeratin 7-positive hepatocytes compressed by the tumor. Importantly, in 5 of 40 patients (12.5%, 95% confidence interval = 5.0-26.6), additional small and superficially located lesions were detected using NIR fluorescence, and were otherwise undetectable by preoperative computed tomography, intraoperative ultrasound, visual inspection, and palpation. CONCLUSIONS: NIR fluorescence imaging, even when used with a nontargeted, clinically available NIR fluorophore, is complementary to conventional imaging and able to identify missed lesions by other modalities.
BACKGROUND: The fundamental principle of oncologic surgery is the complete resection of malignant cells. However, small tumors are often difficult to find during surgery using conventional techniques. The objectives of this study were to determine if optical imaging, using a contrast agent already approved for other indications, could improve hepatic metastasectomy with curative intent, to optimize dose and timing, and to determine the mechanism of contrast agent accumulation. METHODS: The high tissue penetration of near-infrared (NIR) light was exploited by use of the FLARE (Fluorescence-Assisted Resection and Exploration) image-guided surgery system and the NIR fluorophore indocyanine green in a clinical trial of 40 patients undergoing hepatic resection for colorectal cancer metastases. RESULTS: A total of 71 superficially located (< 6.2 mm beneath the liver capsule) colorectal liver metastases were identified and resected using NIR fluorescence imaging. Median tumor-to-liver ratio was 7.0 (range, 1.9-18.7) and no significant differences between time points or doses were found. Indocyanine green fluorescence was seen as a rim around the tumor, which is shown to be entrapment around cytokeratin 7-positive hepatocytes compressed by the tumor. Importantly, in 5 of 40 patients (12.5%, 95% confidence interval = 5.0-26.6), additional small and superficially located lesions were detected using NIR fluorescence, and were otherwise undetectable by preoperative computed tomography, intraoperative ultrasound, visual inspection, and palpation. CONCLUSIONS: NIR fluorescence imaging, even when used with a nontargeted, clinically available NIR fluorophore, is complementary to conventional imaging and able to identify missed lesions by other modalities.
Authors: Edward Leen; Piercarlo Ceccotti; Susan J Moug; Paul Glen; John MacQuarrie; Wilson J Angerson; Thomas Albrecht; Joachim Hohmann; Anja Oldenburg; Jorg Peter Ritz; Paul G Horgan Journal: Ann Surg Date: 2006-02 Impact factor: 12.969
Authors: M Hutteman; J R van der Vorst; J S D Mieog; B A Bonsing; H H Hartgrink; P J K Kuppen; C W G M Löwik; J V Frangioni; C J H van de Velde; A L Vahrmeijer Journal: Eur Surg Res Date: 2011-06-30 Impact factor: 1.745
Authors: Gooitzen M van Dam; George Themelis; Lucia M A Crane; Niels J Harlaar; Rick G Pleijhuis; Wendy Kelder; Athanasios Sarantopoulos; Johannes S de Jong; Henriette J G Arts; Ate G J van der Zee; Joost Bart; Philip S Low; Vasilis Ntziachristos Journal: Nat Med Date: 2011-09-18 Impact factor: 53.440
Authors: Timothy M Pawlik; Charles R Scoggins; Daria Zorzi; Eddie K Abdalla; Axel Andres; Cathy Eng; Steven A Curley; Evelyne M Loyer; Andrea Muratore; Gilles Mentha; Lorenzo Capussotti; Jean-Nicolas Vauthey Journal: Ann Surg Date: 2005-05 Impact factor: 12.969
Authors: Wilmar de Graaf; Stephanie Häusler; Michal Heger; Tessa M van Ginhoven; Gert van Cappellen; Roelof J Bennink; Gerd A Kullak-Ublick; Rolf Hesselmann; Thomas M van Gulik; Bruno Stieger Journal: J Hepatol Date: 2010-10-01 Impact factor: 25.083
Authors: Y Fong; A M Cohen; J G Fortner; W E Enker; A D Turnbull; D G Coit; A M Marrero; M Prasad; L H Blumgart; M F Brennan Journal: J Clin Oncol Date: 1997-03 Impact factor: 44.544
Authors: Henk G van der Poel; Tessa Buckle; Oscar R Brouwer; Renato A Valdés Olmos; Fijs W B van Leeuwen Journal: Eur Urol Date: 2011-04-01 Impact factor: 20.096
Authors: Alexander L Vahrmeijer; Merlijn Hutteman; Joost R van der Vorst; Cornelis J H van de Velde; John V Frangioni Journal: Nat Rev Clin Oncol Date: 2013-07-23 Impact factor: 66.675
Authors: Karl J Oldhafer; Tim Reese; Mohammad Fard-Aghaie; Alina Strohmaier; Georgios Makridis; Alexandros Kantas; Kim C Wagner Journal: Chirurg Date: 2019-11 Impact factor: 0.955
Authors: Mitchell S Fourman; Adel Mahjoub; Jon B Mandell; Shibing Yu; Jessica C Tebbets; Jared A Crasto; Peter E Alexander; Kurt R Weiss Journal: Clin Orthop Relat Res Date: 2018-03 Impact factor: 4.176
Authors: Jeffery Chakedis; Lawrence A Shirley; Alicia M Terando; Roman Skoracki; John E Phay Journal: Ann Surg Oncol Date: 2018-08-03 Impact factor: 5.344